JAGX shows severe financial distress with cash depleting 88% to under $1M while current liabilities doubled and operating losses expanded 49%.
The company is approaching a critical liquidity crisis with less than $1M in cash remaining while owing over $40M in current liabilities, creating immediate going concern risks. The 51% increase in R&D spending amid this cash crunch suggests either poor capital allocation or desperation to achieve near-term milestones before running out of funds.
JAGX's financial position deteriorated dramatically with cash collapsing from $8.0M to $968K (-88%) while current liabilities surged 106% to $40.7M, creating an unsustainable liquidity mismatch. Operating losses widened 49% to -$45.9M driven by a 51% spike in R&D expenses to $25.0M, while total assets contracted 28% as the company burned through resources. Despite stockholders' equity increasing 61% (likely from equity raises or conversions), the overall picture signals acute financial distress requiring immediate capital infusion or dramatic cost cuts to avoid insolvency.
Current liabilities surged 106.3% — significant near-term obligations; verify ability to meet short-term debt.
Cash declined 87.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Capex reduced 79.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Equity base grew 61.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.
R&D investment increased 50.9% — signals commitment to future product development, though near-term margin impact.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 39.2% — review whether driven by operations, interest costs, or non-recurring items.
Current assets declined 36.8% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 28.3% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →